Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 3, 1999, Pages 258-264

  Murayama, Nobuyuki ^a   Tanaka, Makoto ^b   Kunitada, Satoshi ^b   Yamada, Hirohisa ^b   Inoue, Takashi ^b   Terada, Yasuko ^b   Fujita, Masami ^b   Ikeda, Yasuo ^b  

^a DAIICHI SANKYO CO   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PLACEBO;

ADULT; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BLEEDING TIME; BLOOD CLOTTING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN RESIDENCE TIME; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANALYSIS OF VARIANCE; ANTICOAGULANTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BLEEDING TIME; DOUBLE-BLIND METHOD; FACTOR XA; HUMANS; INJECTIONS, INTRAVENOUS; JAPAN; LINEAR MODELS; MALE; NAPHTHALENES; PROPIONIC ACIDS; REFERENCE VALUES;

EID: 0032864368     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70033-0     Document Type: Article

References (20)

1. 1. Nagahra T, Yokoyama Y, Inamura K, Katakura S, Komoriya S, Yamaguchi H, et al. Dibasic (amidino-aryl)-propanoic acid derivative as novel blood coagulant factor Xa inhibitors. J Med Chem 1994;37:1200-7.
2. 2. Katakura S, Nagahara T, Hara T, Iwamoto M. A novel factor Xa inhibitor: structure-activity relationships and selectivity between factor Xa and thrombin. Biochem Biophys Res Commun 1993;197:965-72.
3. 3. Hara T, Yokoyama A, Tanabe K, Ishihara H, Iwamoto M. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 1995;74:635-9.
4. 4. Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994;71:314-9.
5. 5. Milton TS, Robert H, Wolfram B. Crystal structures of factor Xa specific inhibitors in complex with trypsin: structural grounds for inhibitors of factor Xa and selectivity against thrombin. FEBS Lett 1995;375:103-7.
6. 6. Hans B, Anja K, Wolfram B, Robert H, Wolfgang S, Klaus W, et al. X-ray structure of active site-inhibited clotting factor Xa. J Biol Chem 1996;271:29988-92.
7. 7. Zhaolan L, Michael EJ. Proposed cation-π mediated binding by factor Xa: a novel enzymatic mechanism for molecular recognition. FEBS Lett 1995;370:1-5.
8. 8. Morishima Y, Tanabe K, Terada Y, Hara T, Kunitada S. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost 1997;78:1366-71.
9. 9. Hara T, Morishima Y, Ishihara H, Murayama N, Tanaka S, Sudo K, et al. Inhibition of thrombin generation effectively prevents thrombus formation without aggravation of bleeding [abstract]. Thromb Haemost 1995;73:1308.
10. 10. Murayama N, Tanaka S, Kikuchi T, Nakaoka M, Sudo K. Radioimmunoassay method for DX-9065a, an anticoagulant agent: development, evaluation and application to human plasma. J Pharm Biomed Anal 1996;14:1435-45.
11. 11. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical methods validation: bioavailability bioequivalence and pharmacokinetic studies. J Pharm Sci 1992;81:309-12.
12. 12. Murayama N, Sudo K. High-performance liquid chromatographic method for determination of DX-9065a, a novel anticoagulant, in human urine and feces using cation-exchange solid-phase extraction. J Chromatogr Biomed Appl 1997;692:389-96.
13. 13. Iwamoto M, Honda Y. Study of sensitive monitor method for DX-9065a. J Clin Lab Inst Reag 1994;17:1034-9.
14. 14. Deykin D. Anticoagulant therapy, In: Colman RW, Hirsh J, Marder VI, Salzman EW, editors. Hemostasis and thrombosis: basic principals and clinical practice. Philadelphia: JB Lippincott; 1982. p. 1000-12.
15. 15. Salzman EW, Davies GC. Prophylaxis of thromboembolism: analyses of cost effectiveness. Ann Surg 1980; 191:207-18.
16. 16. Collins R, Scrimgeour A, Yusuf S, Phill D, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by preoperative administration of subcutaneous heparin. N Engl J Med 1988;318:1162-73.
17. 17. Hirsh J, Fuster V. Guide to anticoagulant therapy part 2: Oral anticoagulants. Circulation 1994;89:1469-80.
18. 18. Iorio A, Agnelli G. Pharmacokinetic optimization of the treatment of deep vein thrombosis. Clin Pharmacokinet 1997;32:145-72.
19. 19. Al-Obeidi F, Ostrem JA. Factor Xa inhibitors by classical and combinatorial chemistry. DDT 1998;3:223-31.
20. 20. Estes JW. The kinetics of heparin. Ann NY Acad Sci 1971;179:187-204.